menu

Psychosis in Schizophrenia: Could a Non-D2-Receptor Binding Drug Be the Key?

Be part of the knowledge.
Register

We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?

Register for free

Treating Psychosis in Schizophrenia: Could a Non-D2-Receptor Binding Drug Be the Key?

ReachMD Healthcare Image
Restart
Resume
Choose a format
Media formats available:
Completing the pre-test is required to view this content.
Completing the pre-survey is required to view this content.
Details
Presenters
Related
  • Overview

    Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract.

    To review the full abstract, please click here. 

Recommended
Details
Presenters
Related
  • Overview

    Could an oral compound represent a new class of psychotropic agent with a non-D2-receptor binding mechanism of action for the treatment of psychosis in schizophrenia? That’s what the authors of a recent study wanted to find out, and it’s what Dr. Matt Birnholz explores in this Audio Abstract.

    To review the full abstract, please click here. 

Schedule7 Dec 2022